Phantom Neuro

Executive Summary

Phantom Neuro is a Houston-based neurotechnology startup developing the Phantom X, a minimally invasive implantable muscle-machine interface that decodes electrical signals from muscles to enable precise, real-time control of robotic prosthetics and exoskeletons. Founded in 2020, the company addresses the limitations of current prosthetic technologies, which often lack natural, intuitive control, leading to high abandonment rates. Phantom X aims to restore natural movement and enhance human capability by providing a bidirectional interface that is less invasive than traditional brain-computer interfaces and more functional than surface electromyography. The company is currently in the pre-clinical phase, focusing on refining its implant design and conducting animal studies. With a strong intellectual property portfolio and a seasoned team in neurotechnology and medical devices, Phantom Neuro is poised to advance to first-in-human trials within the next 12-18 months. The technology has the potential to significantly improve quality of life for amputees and individuals with limb differences, while also opening applications in human augmentation. Key upcoming milestones include securing Series A funding, obtaining FDA Breakthrough Device Designation, and initiating first clinical studies.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round Close75% success
• Q4 2026FDA Breakthrough Device Designation70% success
• Q2 2027First-in-Human Clinical Trial Initiation60% success